NCT06881004 Biliary Dilatation National Special Disease Cohort in China
| NCT ID | NCT06881004 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tsinghua Chang Gung Hospital |
| Condition | Choledochal Cyst |
| Study Type | OBSERVATIONAL |
| Enrollment | 6,000 participants |
| Start Date | 2025-03-19 |
| Primary Completion | 2035-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 6,000 participants in total. It began in 2025-03-19 with a primary completion date of 2035-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a multicenter, bidirectional cohort study aimed at continuously enrolling patients with biliary dilatation from 25 medical centers in China. It will collect comprehensive life-cycle data from the cohort to establish a Chinese cohort for bile duct dilatation. Based on this cohort, the study seeks to clarify the epidemiological characteristics, pathological features, standard classification, disease progression, cancer risk, and optimal timing for surgical intervention in patients with bile duct dilatation. Additionally, it will compare the perioperative risks, long-term outcomes, and quality of life among different types of patients (including Todani types I, IVa, and V) following surgical treatment, to establish standardized surgical treatment strategies for each type.
Eligibility Criteria
Inclusion Criteria: 1. Patients who have been definitive diagnosed with biliary dilation. 2. Patients aged between 0 and 80 years old, regardless of gender. 3. In line with the principle of informed consent: For the retrospective cohort of biliary dilation, exemption from signing the informed consent form is applied for, while for the prospective cohort, signing the informed consent form is required. Exclusion Criteria: * None
Contact & Investigator
Shuo Jin, PhD
PRINCIPAL INVESTIGATOR
Beijing Tsinghua Chang Gung Hospital
Frequently Asked Questions
Who can join the NCT06881004 clinical trial?
This trial is open to participants of all sexes, up to 80 Years, studying Choledochal Cyst. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06881004 currently recruiting?
Yes, NCT06881004 is actively recruiting participants. Contact the research team at 809262038@qq.com for enrollment information.
Where is the NCT06881004 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06881004 clinical trial?
NCT06881004 is sponsored by Beijing Tsinghua Chang Gung Hospital. The principal investigator is Shuo Jin, PhD at Beijing Tsinghua Chang Gung Hospital. The trial plans to enroll 6,000 participants.